Oral COVID-19 Antiviral Uptake Among a Highly Vaccinated US Cohort of Adults With SARS-CoV-2 Infection Between December 2021 and October 2022.

"Potential conflicts of interest. D.N. receives consulting fees from Gilead Sciences and AbbVie. CUNY received research support from Pfizer during the conduct of this study that was paid directly to CUNY. D.N. is the Principal Investigator on the research grant to the City University of New York School of Public Health that provided support for this study. L.P., J.M.Z., K.E.A., T.M.P., and J.M.M. are employees of Pfizer and may hold stock or stock options with Pfizer. All other authors report no potential conflicts."

"Financial support. Funding for this project was provided by the National Institute of Allergy and Infectious Diseases (NIAID), award number UH3AI133675 (MPIs: D. Nash and C. Grov), the CUNY Institute for Implementation Science in Population Health ( cunyisph.org ), and the COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy. The NIH played no role in the production of this manuscript, nor does it necessarily endorse the findings. This study was sponsored by Pfizer. The study design was developed by CUNY with input from Pfizer. CUNY collected and analyzed the data. Pfizer did not participate in the collection or analysis of data. CUNY and Pfizer participated in the interpretation of data, in the writing of the report, and in the decision to submit the article for publication. Financial support ."